Navigation Links
SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
Date:7/26/2011

p>

For the quarter ended June 30, 2011, the Company's marketing and selling expenses decreased 38%, or $33,000, to $53,000, compared to $86,000 for the same period in 2010.  This decrease was primarily due to a reduction in sales commissions and royalties due to lower royalty revenues.

The Company recorded a gain of $103,000 on research and development activity compared to an expense of $256,000 for the same period in 2010.  The gain was a result of receiving proceeds during the quarter on sale of certain laboratory equipment of $120,000, combined with lower research and development expenses following the elimination of its laboratory activities.

General and administrative expenses increased 2%, or $13,000, to $585,000 for the three months ended June 30, 2011, compared to approximately $572,000 for the same period in 2010.   The increase was primarily due to recognition of $61,000 in accelerated depreciation expense related to leasehold improvements as a result of a reduction in the term of our headquarters lease. This increase was offset by a decrease in office expense.

Other income decreased 106%, or $222,000, to an expense of $12,000 for the three months ended June 30, 2011, compared to income of $210,000 for the comparable period in 2010. This decrease is due to a change in unrealized gain (loss) on the fair value of a warrant to purchase common stock.  

Net loss increased 12%, or $58,000, to $539,000 for the three months ended June 30, 2011, compared to $481,000 for the same period in 2010. The increase in net loss reflects lower revenues and the change in the unrealized gain (loss) on fair value of warrant to purchase common stock.

Comparison of the Year to Date Six Months Ended June 30, 2011 and 2010 Total revenues, which consist of licensing fees, research and development revenues, and royalty revenue from SCOLR's collaboration agreements, decreased 51%, or $197,000, to $192,000 for the si
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. SCOLR Pharma, Inc. First Quarter 2011 Financial Results
2. SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
3. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
4. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
5. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
6. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
7. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
8. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
9. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
10. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
11. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Kan. , July 24, 2014  Parnell ... two compounds that will be added to Parnell,s ... Australian-based CIMTECH Pty Ltd, a biotechnology company. The ... 122 have shown promise in bone regeneration and ... to develop the compounds for the veterinary market ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Pieris AG presented the results ... most advanced Anticalin ® , PRS-050, an anti-VEGF ... Conference held in San Francisco, California.  The dose-escalation ... tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PRS-050 ...
... /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... operator of the largest network of radiotherapy and diagnostic imaging ... for the third quarter ended September 30, 2011. ... revenues were RMB124.7 million ($19.6 million)(A) in the third quarter ...
Cached Medicine Technology:Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 2Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 3Concord Medical Reports Third Quarter 2011 Financial Results 2Concord Medical Reports Third Quarter 2011 Financial Results 3Concord Medical Reports Third Quarter 2011 Financial Results 4Concord Medical Reports Third Quarter 2011 Financial Results 5Concord Medical Reports Third Quarter 2011 Financial Results 6Concord Medical Reports Third Quarter 2011 Financial Results 7Concord Medical Reports Third Quarter 2011 Financial Results 8Concord Medical Reports Third Quarter 2011 Financial Results 9Concord Medical Reports Third Quarter 2011 Financial Results 10Concord Medical Reports Third Quarter 2011 Financial Results 11Concord Medical Reports Third Quarter 2011 Financial Results 12Concord Medical Reports Third Quarter 2011 Financial Results 13Concord Medical Reports Third Quarter 2011 Financial Results 14Concord Medical Reports Third Quarter 2011 Financial Results 15
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... dismissal and summary judgment in two DePuy Pinnacle hip ... paving the way for the claims to go before ... reports. In an opinion rendered on July 18th, U.S. ... Texas, ruled that the two Plaintiffs’ claims may proceed ...
(Date:7/25/2014)... As reported by the New Orleans Advocate in ... (7/3), the state of Louisiana has recently seen a large ... cocaine. Officials believe the increase is due to a misconception ... marijuana. However, both doctors and police confirm that that belief ... call it “poison,” doctors have acknowledged that the Louisiana Poison ...
(Date:7/25/2014)... Youngstown, Ohio (PRWEB) July 25, 2014 ... processed foods? How to know? , Read the labels! ... labels and determine how it relates to health during ... 12:30 p.m. Aug. 1 at Humility House, 755 Ohltown ... Lackey will lead an informational discussion and answer questions. ...
(Date:7/25/2014)... of America (GSA) the nation,s largest ... has chosen Heather M. Young, PhD, RN, ... the 2014 recipient of the Doris Schwartz Gerontological ... by GSA,s Health Sciences Section, is given to ... outstanding and sustained contribution to gerontological nursing research. ...
(Date:7/25/2014)... As reported by Wood TV 8 in the article ... a nearly 500-person increase in heroin related overdose deaths in ... 1999 and 2002, the toll increased to 728 during the ... drug users in Michigan have turned to heroin after getting ... price of both substances, noting that an 80-milligram pill can ...
Breaking Medicine News(10 mins):Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Learn to Decipher Food Labels at Humility House 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2
... decision to lower requirements for designation , , WEDNESDAY, ... U.S. government decision to lower the benchmark for ... new Johns Hopkins Medical Institutions study reports the ... 14 transplants a year. , The Centers for ...
... A new study from the Monell Center increases ... nausea and vomiting that often afflict patients undergoing ... of new approaches to combat these debilitating side ... the nausea and vomiting that accompany chemotherapy treatment, ...
... (Nasdaq: AMCS ),a leader in radiology and medical image and ... investors at the UBS Global Healthcare Services Conference in New,York., ... -- Tuesday, February 12, 2008 ... 11:30 a.m. (Eastern Time), ...
... Idaho, January 30, 2008 Preventative heart healthcare gains ... NHWK), announced its involvement as the exclusive radiology provider ... Initiative is a joint research effort to advance the ... to be the primary underlying cause of heart attacks ...
... Thanks to Nutrition on the Go, an,innovative new program ... more than 1,700 restaurants nationwide is available in,a flash through ... and menu item., Not cell phone savvy? No worries. ... menu item you need help with, then send that info ...
... Jan. 30 Onmark, a leading,national group ... McKesson Specialty company, today announced the launch ... goal of helping community-based,oncology practices improve the ... which is facilitated through OTN,s industry-leading Lynx,Mobile(TM) ...
Cached Medicine News:Health News:Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals 2Health News:Explaining chemotherapy-associated nausea 2Health News:AMICAS to Present at UBS Global Healthcare Services Conference 2Health News:NightHawk Radiology exclusive radiology provider for high-risk plaque research initiative 2Health News:Ring Up Instant Nutrition Info via Text Message to DIET1 (34381) 2Health News:Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives 2Health News:Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives 3Health News:Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives 4